- The folks at Gustave Roussy, Cancer Campus, Grand Paris are studying the effects of Blood test on Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer in females ages 18 years and older. This clinical trial is slated to start February 2013 and is expected to end circa February 2018.
This study is officially titled, "Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery."
|Recruiting||Institut Gustave Roussy|
Villejuif, Val de Marne, 94805
France - map
|Monica ARNEDOS, MD||0142114371|
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.